Empagliflozin + Other SGLT2 inhibitors + Other non-insulin GLDs

Pre-clinicalCompleted
0 watching 0 views this week๐Ÿ’ค Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Type 2 Diabetes

Conditions

Type 2 Diabetes

Trial Timeline

Sep 10, 2016 โ†’ Oct 14, 2016

About Empagliflozin + Other SGLT2 inhibitors + Other non-insulin GLDs

Empagliflozin + Other SGLT2 inhibitors + Other non-insulin GLDs is a pre-clinical stage product being developed by Eli Lilly for Type 2 Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT03050619. Target conditions include Type 2 Diabetes.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT03050619Pre-clinicalCompleted